Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:CRSP NASDAQ:PGEN NASDAQ:PTCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$24.53+2.4%$24.13$13.40▼$26.65$4.14B0.752.15 million shs692,482 shsCRSPCRISPR Therapeutics$58.58-4.3%$56.99$30.04▼$71.13$5.41B1.812.54 million shs1.46 million shsPGENPrecigen$3.87-0.6%$2.81$0.65▼$5.22$1.16B1.824.00 million shs1.98 million shsPTCTPTC Therapeutics$61.39+2.8%$50.73$34.57▼$62.18$4.89B0.531.10 million shs1.14 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-2.88%-3.54%-5.41%+4.40%+48.45%CRSPCRISPR Therapeutics+5.79%+13.97%+2.44%+37.72%+28.17%PGENPrecigen+8.36%-5.81%+32.31%+161.07%+289.08%PTCTPTC Therapeutics+1.20%+2.17%+22.27%+18.36%+76.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$24.53+2.4%$24.13$13.40▼$26.65$4.14B0.752.15 million shs692,482 shsCRSPCRISPR Therapeutics$58.58-4.3%$56.99$30.04▼$71.13$5.41B1.812.54 million shs1.46 million shsPGENPrecigen$3.87-0.6%$2.81$0.65▼$5.22$1.16B1.824.00 million shs1.98 million shsPTCTPTC Therapeutics$61.39+2.8%$50.73$34.57▼$62.18$4.89B0.531.10 million shs1.14 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-2.88%-3.54%-5.41%+4.40%+48.45%CRSPCRISPR Therapeutics+5.79%+13.97%+2.44%+37.72%+28.17%PGENPrecigen+8.36%-5.81%+32.31%+161.07%+289.08%PTCTPTC Therapeutics+1.20%+2.17%+22.27%+18.36%+76.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.65Moderate Buy$29.6520.88% UpsideCRSPCRISPR Therapeutics 2.47Hold$71.6022.22% UpsidePGENPrecigen 2.80Moderate Buy$8.25113.40% UpsidePTCTPTC Therapeutics 2.53Moderate Buy$69.0012.40% UpsideCurrent Analyst Ratings BreakdownLatest PGEN, CRSP, PTCT, and ACAD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025ACADACADIA PharmaceuticalsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/11/2025ACADACADIA PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $39.009/9/2025ACADACADIA PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$36.00 ➝ $39.009/3/2025PTCTPTC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$118.008/26/2025CRSPCRISPR TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/20/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$79.00 ➝ $73.008/20/2025PTCTPTC TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$76.00 ➝ $71.008/20/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$82.00 ➝ $76.008/19/2025PGENPrecigenCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform8/19/2025PGENPrecigenJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$6.00 ➝ $8.008/19/2025PGENPrecigenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.50(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$957.80M4.32$0.70 per share35.00$4.40 per share5.57CRSPCRISPR Therapeutics$37.31M142.80N/AN/A$22.64 per share2.59PGENPrecigen$3.92M293.87N/AN/A$0.13 per share29.74PTCTPTC Therapeutics$806.78M6.04N/AN/A($14.24) per share-4.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$226.45M$1.3318.4532.276.2521.80%14.69%9.41%11/5/2025 (Estimated)CRSPCRISPR Therapeutics-$366.25M-$5.43N/AN/AN/A-1,229.43%-20.05%-17.09%11/4/2025 (Estimated)PGENPrecigen-$126.24M-$0.42N/AN/AN/A-2,868.66%-842.83%-78.98%11/13/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.978.83N/AN/A35.65%-106.31%30.61%11/6/2025 (Estimated)Latest PGEN, CRSP, PTCT, and ACAD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025PGENPrecigen-$0.14-$0.11+$0.03-$0.09$0.67 million$0.86 million8/7/2025Q2 2025PTCTPTC Therapeutics-$1.07-$0.83+$0.24-$0.83$173.01 million$178.88 million8/6/2025Q2 2025ACADACADIA Pharmaceuticals$0.14$0.16+$0.02$0.16$263.07 million$264.57 million8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.47-$1.29+$0.18-$2.40$6.44 million$0.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.912.83CRSPCRISPR TherapeuticsN/A16.6116.61PGENPrecigenN/A2.712.71PTCTPTC TherapeuticsN/A3.623.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%CRSPCRISPR Therapeutics69.20%PGENPrecigen33.51%PTCTPTC TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals28.30%CRSPCRISPR Therapeutics4.10%PGENPrecigen47.10%PTCTPTC Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510168.71 million120.97 millionOptionableCRSPCRISPR Therapeutics46090.95 million87.22 millionOptionablePGENPrecigen190297.97 million157.63 millionOptionablePTCTPTC Therapeutics1,41079.44 million75.07 millionOptionablePGEN, CRSP, PTCT, and ACAD HeadlinesRecent News About These CompaniesInsider Selling: PTC Therapeutics (NASDAQ:PTCT) Director Sells 15,705 Shares of StockSeptember 17 at 6:02 AM | insidertrades.comIntech Investment Management LLC Buys 15,167 Shares of PTC Therapeutics, Inc. $PTCTSeptember 17 at 3:08 AM | marketbeat.comBank of America Securities Keeps Their Buy Rating on PTC Therapeutics (PTCT)September 16 at 8:23 PM | theglobeandmail.comPTC Therapeutics (NASDAQ:PTCT) VP Sells $1,382,504.00 in StockSeptember 16 at 5:20 PM | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 24,585 SharesSeptember 16 at 5:20 PM | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) VP Sells $1,382,504.00 in StockSeptember 16 at 4:33 AM | insidertrades.comPTC Therapeutics, Inc. $PTCT Stake Reduced by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.September 15 at 3:30 AM | marketbeat.comEllsworth Advisors LLC Makes New $588,000 Investment in PTC Therapeutics, Inc. $PTCTSeptember 14 at 5:16 AM | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Director David Southwell Sells 12,000 SharesSeptember 13, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Sets New 1-Year High - Here's WhySeptember 13, 2025 | marketbeat.comPTC Therapeutics, Inc. $PTCT Shares Sold by Jacobs Levy Equity Management Inc.September 13, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Director Sells $700,080.00 in StockSeptember 12, 2025 | insidertrades.comBayforest Capital Ltd Purchases New Shares in PTC Therapeutics, Inc. $PTCTSeptember 12, 2025 | marketbeat.comEric Pauwels Sells 39,850 Shares of PTC Therapeutics (NASDAQ:PTCT) StockSeptember 11, 2025 | marketbeat.comPTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKUSeptember 11, 2025 | msn.comInsider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 39,850 Shares of StockSeptember 10, 2025 | insidertrades.comAQR Capital Management LLC Boosts Stake in PTC Therapeutics, Inc. $PTCTSeptember 10, 2025 | marketbeat.comCantor Fitzgerald Keeps Their Buy Rating on PTC Therapeutics (PTCT)September 8, 2025 | theglobeandmail.comPTC Therapeutics, Inc. (PTCT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 8, 2025 | seekingalpha.comPTC Therapeutics, Inc. $PTCT Shares Bought by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $69.00 Consensus Price Target from AnalystsSeptember 8, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePGEN, CRSP, PTCT, and ACAD Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$24.53 +0.57 (+2.36%) As of 02:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.CRISPR Therapeutics NASDAQ:CRSP$58.58 -2.61 (-4.26%) As of 02:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Precigen NASDAQ:PGEN$3.87 -0.02 (-0.62%) As of 02:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.PTC Therapeutics NASDAQ:PTCT$61.39 +1.70 (+2.85%) As of 02:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
